Thiopurine methyltransferase activity in red blood cells of dogs

Journal of Veterinary Internal Medicine

Volumn 18, Issue 2, 2004, Pages 214-218

  Kidd, Linda Benjamin ^a,c   Salavaggione, Oreste E ^b   Szumlanski, Carol L ^b   Miller, Jackie L ^a   Weinshilboum, Richard M ^b   Trepanier, Lauren ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Drug metabolism; Drug toxicity; Pharmacogenetics

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ANIMAL CELL; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; ENZYME METABOLISM; ERYTHROCYTE; GENETIC POLYMORPHISM; HEPARINIZATION; NONHUMAN; RADIOCHEMISTRY;

ANIMALS; DOGS; ERYTHROCYTES; FEMALE; MALE; METHYLTRANSFERASES; PEDIGREE; REFERENCE VALUES;

ANIMALIA; CANIS FAMILIARIS;

EID: 1642305900     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<214:TMAIRB>2.0.CO;2     Document Type: Article

References (47)

1. Stolk JN, Boerbooms AMT, DeAbreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1858-1866.
2. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-718.
3. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12:429-436.
4. Moriello KA, Bowen D, Meyer DJ. Acute pancreatitis in two dogs given azathioprine and prednisone. J Am Vet Med Assoc 1987; 191:695-696.
5. Houston DM, Taylor JA. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. Can Vet J 1991;32:496-497.
6. Beale KM. Azathioprine for treatment of immune-mediated diseases of dogs and cats. J Am Vet Med Assoc 1988;192:1316-1318.
7. Beale KM, Altman D, Clemmons RR, Bolon B. Systemic toxicosis associated with azathioprine administration in domestic cats. Am J Vet Res 1992;53:1236-1240.
8. Rinkhardt NE, Kruth SA. Azathioprine-induced bone marrow toxicity in four dogs. Can Vet J 1996;37:612-613.
9. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-339.
10. Lewis RM. Rheumatoid arthritis. Vet Clin North Am 1994;24: 697-703.
11. Plumb DC. Veterinary Drug Handbook, 3rd ed. Ames, IA: Iowa State University Press; 1999.
12. Christie NT, Drake S, Meyn RE, Nelson JA. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res 1984;44:3665-3671.
13. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptourine in acute lymphoblastic leukemia. Am J Pediatr Hematol/Oncol 1993;15:80-86.
14. Coulthard SA, Rabello C, Robson J, et al. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Hematol 2000;110:599-604.
15. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monitoring 1996;18:328-334.
16. Micheli V, Jacomelli G, Fioravanti A, et al. Thiopurine methyltransferase activity in the erythrocytes of adults and children: An HPLC-linked assay. Clin Chim Acta 1997;259:161-168.
17. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713.
18. Dubinsky MC, Yang HY, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122: 904-915.
19. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-229.
20. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Phamacol Ther 1987;41:18-25.
21. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. J Hum Genet 1980;32:651-662.
22. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-154.
23. Evans WE, Homer M, Qin Chu Y, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine deficient child with acute lymphocytic leukemia. J Pediatr 1991;119: 985-989.
24. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:2293-2301.
25. Sebbag L, Boucher P, Davelu P, et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000;69: 1524-1527.
26. Andersen JB, Szumlanski CL, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/ methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Pediatr 1998;87:108-111.
27. Dervieux T, Medard Y, Baudouin V, et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. J Clin Pharmacol 1999;48:793-800.
28. Jackson AP. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 1997;136:132-148.
29. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-614.
30. Klemetsdal B, Tollefsen E, Loennechen T, et al. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:24-31.
31. McLeod HL, Pritchard SC, Githang J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9:773-776.
32. Collie-Duguid ESR, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
33. Kumagai K, Hiyama K, Ishioka S, et al. Genotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001;11:275-278.
34. Ishioka S, Hiyama K, Sato H, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999;38:944-947.
35. Ameyaw M-M, Collie-Duguid ESR, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanian populations. Hum Mol Genet 1999;8:367-370.
36. Lowenthal A, Meyerstein N, Ben-Zvi Z. Thiopurine methyltransferase activity in the Jewish population of Israel. J Clin Pharmacol 2001;57:43-46.
37. Dewit O, Vanheuverzwyn R, Deasager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:79-85.
38. Szumlanski CL, Weinshilboum RM. Sulfasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-459.
39. Weyer N, Kroplin T, Fricke L, Iven H. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001;57:129-136.
40. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-475.
41. Bergan S, Rugstad HE, Klemetsdal B, et al. Possibilities for therapeutic drug monitoring of azathioprine: 6-Thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther Drug Monitoring 1997;19:318-326.
42. White S, Rosychuk RAW, Outerbridge DA, et al. Thiopurine methyltransferase in red blood cells of dogs, cats and horses. J Vet Intern Med 2000;14:499-502.
43. Foster AP, Shaw SE, Duley JA, et al. Demonstration of thiopurine methyltransferase activity in the erythrocytes of cats. J Vet Intern Med 2000;2000:552-554.
44. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-333.
45. Dawson B, Trapp R. Basic and Clinical Biostatistics, 3rd ed. Norwalk, CT: Appleton and Lange; 2000.
46. Kader HA, Wenner WJ, Telega GW, Baldassano RN. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000;30:409-413.
47. Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematous patients taking azathioprine. Rheumatology 1999;38:640-644.